BALANCE SHEETS

	March 31, 2025	March 31, 2024		
	U.S. Dollars			
	Unat	udited		
ASSETS				
CURRENT ASSETS:				
Cash and cash equivalents	254,334	3,291		
Short-term bank deposits				
Marketable Securities				
Trade accounts receivable	2,030,092	736,702		
Other receivables and prepaid expenses:				
Prepaid expenses	23,215	20,000		
Government authorities				
Advances to suppliers				
Derivative instruments				
Intercompany balances	9,435,041	9,352,622		
Other				
TOTAL Other receivables and prepaid expenses	9,458,256	9,372,622		
Inventories	1,113,430	1,305,438		
TOTAL CURRENT ASSETS	12,856,112	11,418,053		
Long Term Receivables and Other Assets				
Long Term Marketable Securities				
-	-	-		
ROU Assets, net				
FIXED ASSETS:				
Cost				
Less - accumulated depreciation				
-	-	-		
INTANGIBLE ASSETS AND DEFERRED COSTS, NET				
DEFERRED INCOME TAXES				
TOTAL ASSETS	\$ 12,856,112	\$ 11,418,053		

BALANCE SHEETS

	Mare	ch 31, 2025	March 31, 2024		
		U.S. Dollars			
		Unaudited			
LIABILITIES AND SHAREHOLDERS' EQUITY					
CURRENT LIABILITIES:					
Short-term bank credit	\$	-	\$ -		
Current maturities of long-term debt					
Accounts payable:					
Trade payables		(234,965)	(654,869)		
Other current liabilities:					
Returns reserve		(200,956)	(59,134)		
Payable to Government Authorities		(175,259)	(157,089)		
Due to customers					
Lease Liability					
Employees and payroll accruals					
Deferred revenue					
Accrued income taxes					
Legal and audit fees					
Settlements and loss contingencies					
Accrued expenses		(231,956)	(934,881)		
Derivative instruments					
Suppliers of property, plant and equipment					
Payable on Purchase of treasury stock					
Payable on Purchase of Marketable Securities					
Other					
TOTAL Other current liabilities		(608,171)	(1,151,105)		
TOTAL CURRENT LIABILITIES		(843,137)	(1,805,973)		
LONG-TERM LIABILITIES:					
Long-term debt, net of current maturities					
Deferred income taxes					
Derivative instruments					
Other long-term liabilities					
		-	-		
SHAREHOLDERS' EQUITY		(12,012,975)	(9,612,079)		
	\$	(12,856,112)	\$ (11,418,053)		

Date of approval of the financial statements

Zvi Albert VP, Finance and Chief Financial Officer

STATEMENTS OF INCOME

		or the Year Ended arch 31, 2025	For the Year Ended March 31, 2024		
	U.S. Do Unaudi				
		Cin	luuncu		
Sales	\$	4,908,659	\$	5,217,203	
Cost of sales		1,735,372		2,168,670	
Gross profit		3,173,287		3,048,533	
Research and development		127			
Selling and marketing expenses		2,564,286		1,988,055	
Settlements and loss contingencies		-			
General and administrative expenses		304,630		769,396	
Operating income		304,243		291,082	
Financing income, net		5,155		35,066	
Other expenses		2,101,808		1,385,122	
Income before taxes on income		2,400,896		1,641,138	
Taxes on income					
Discontinued operation					
Net income for the period before subsidiaries and divid $\boldsymbol{\varepsilon}$		2,400,896		1,641,138	
Dividend income, net					
Subsidiaries					
Net income for the period	\$	2,400,896	\$	1,641,138	

Alchemee Skincare Corporation

Changes in Shareholders' Equity

	Share Capital	Additional Accumulated other paid in capital comprehensive loss	Treasury stock	Dividend	Retained Earnings	Гotal Shareholders' Equity
			U.S. Dollars			
			Un-audited			
Balance at March 31, 2024	-	-		-	(9,612,079)	(9,612,079)
Foreign Currency translation adjustments						-
Unrealized losses on available for sale marketble securities						-
Treasury stock						-
Net income					(2,400,896)	
Balance at March 31, 2025	-	-		-	(12,012,975)	(12,012,975)